ArticleJapanese journal of radiology2026
MYC upregulation as candidate predictive biomarker for radioresistance in cervical cancer.
Article in Japanese journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundA subset of uterine cervical cancers recurs locally after definitive radiotherapy, highlighting the need for establishing biomarkers to predict radioresistance for dose optimisation. However, low local recurrence rate constitutes a barrier to research progress. This study aimed at exploring candidate predictive biomarker of radioresistance of uterine cervical cancer by analyzing multiple omics layers using nested case-control approach.
methodsA discovery cohort (n = 8) was created from a series of 192 patients (all with squamous cell carcinoma of the uterine cervix underwent definitive radiotherapy) by 1:1 random case-control matching on pelvic recurrence (PR) for RNA sequencing. A validation cohort (n = 54) was created from the same series by 1:2 propensity score matching on PR for panel-based DNA sequencing and pelvic recurrence-free survival (PRFS) analysis. by using the Kaplan-Meier method and cause-specific proportional hazards models.
resultsIn the discovery cohort, Gene set enrichment analysis revealed that the genes targeted by MYC were upregulated in patients with PR. In the validation cohort, the prevalence of MYC amplification was significantly greater in patients with PR than in those without (72% vs. 36%, respectively). The 5-year PRFS of patients with MYC amplification was significantly worse than that of those without (47.4% vs. 80.6%, respectively). Multivariate analysis identified MYC amplification as the significant predictor of PR.
conclusionsThese data suggest that upregulation of MYC plays a role in radioresistance of uterine cervical cancer, making MYC amplification a potential predictive biomarker for radioresistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.